View all results
No results
News
Events
The industry
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Talent platform
Networking platforms
Newsletter
Association
Our mission
Members
Academy
Insight Events
Partners
Team
Media
Add listing
Log in
or
Register
0
Add listing
Alpha-synuclein antibody
Product
prev
next
Leave a review
Bookmark
Share
Report
prev
next
Indicaton
Neurogenerative Diseases
Therapeutic indications
CNS
Type of product
Antibody
Company
AC Immune SA
Table
Phase
Discovery
You may also be interested in
Dipraglurant (mGlu5 NAM) for PD-LID
Milestone: Indication under evaluation Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Featured
Phase II started
GABAb PAM for Chronic cough
We plan to develop our GABAB PAM drug candidate for the treatment of chronic cough. This target is clinically validated with baclofen, an orthosteric agonist of GABAB, is used off label to treat chronic cough patients. However, baclofen’s use is limited by serious side-effects, short half-life and gradual loss of efficacy during chronic treatment. By more precisely targeting the GABAB receptor with a PAM we aim to have a best-in-class treatment with improved tolerability suitable for the chronic nature of this disease. This indication has a significant unmet medical need and represents a solid commercial opportunity. We are in late clinical candidate selection phase and have demonstrated proof-of-concept in animal models of cough with several compounds. Subject to funding, we expect IND enabling studies to begin in 2024.
Featured
Discovery
ADX71149 (mGlu2 PAM) for Epilepsy
ur partnered drug candidate, ADX71149, is a novel orally active mGlu2 PAM for Epilepsy, an indication with a large commercial opportunity as existing therapies frequently provide ineffective control of symptoms or have side effects that discourage adherence. Our partner, Janssen, is conducting a placebo-controlled Phase 2 proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. Cohort 1 have completed the study. Cohort 2, testing a different dose of ADX71149 has completed recruitment and we expect to announce results of the study in Q2 2024. Under our agreement with Janssen, they are responsible for financing the development and commercialization, if any, of ADX71149. Our partner, Janssen, has completed Phase 1 and two Phase 2a clinical trials in schizophrenia and anxious depression, respectively. Janssen has announced that ADX71149 has been extensively profiled in preclinical models of epilepsy showing both standalone activity and in combination with SV2A ligands including Keppra. Janssen has patented the combination of mGlu2 PAM with SV2A ligands for the treatment of epilepsy. The placebo-controlled Phase 2 proof of concept clinical trial of in epilepsy patients since June 2021. On November 14, 2023, we announced that the last patient has been randomized in Cohort 2 and results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohort 1 and Cohort 2 are anticipated for the second quarter of 2024.
Featured
Phase II started
Cart
×
View all results
No results
Facebook
X
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
Reddit
VKontakte
Mail
Copy link
Share via...
This site uses cookies:
Find out more.
Accept
